One of the most studied strategies involves targeting the immunosuppressive interaction between programmed death ligand 1 (PD-L1), which is present on tumour cells, and its receptor, programmed death receptor (PD-1), which is expressed on immune cells, such as activated T cells, natural killer (NK) cells, B cells, macrophages and different subsets of dendritic cells (DCs) (6). This evidence concerns the gene CD274 and neoplasm.